L-cysteine and zinc-L-carnosine in the therapy of chronic atrophic gastritis: clinical efficacy and tolerability
Keywords:
Chronic Atrophic Gastritis, , L-cysteine, zinc-L-carnosine, Pepsinogen I, Gastrin 17, OLGAAbstract
Background and aim: Chronic atrophic gastritis is characterized by gastric atrophy due to loss of the mucosa cells. Clinical manifestations are represented by gastrointestinal symptoms and/or alterations due to macronutrient deficiency. There is no specific therapy for CAG, although some medical devices appear promising: L-cysteine reduces acetaldehyde levels in the stomach , zinc L-carnosine shows direct cytoprotective and anti-inflammatory action. We evaluated, in CAG patients, the therapeutic efficacy and tolerability of both devices on the improvement of gastric functional picture and symptoms as compared to a control group.
Methods: 200 CAG patients were recruited and divided into: Group 1: L-cysteine 300 mg/daily; Group 2: zinc L-carnosine 75 mg/daily; Group 3: control group without any therapy. Patients were followed up for three months to evaluate the efficacy of both molecules and the possible appearance of side effects and adverse events.
Results: Increased serum PGI l (efficacy rate 37.1% and 21.3%) and decreased G17 levels (efficacy rate 41.3% and 58.7%) were found for L-cysteine and zinc L-carnosine, respectively. An improvement or no appearance of new symptoms was detected (65.7% for L-cysteine and 77.3% for zinc L-carnosine). Both devices appeared well tolerated (compliance rate of 100% for L-cysteine and 93.7% for zinc L-carnosine) and side effects were limited to manifestations that resolved after stopping therapy.
Conclusions: Clinical efficacy of both molecules on CAG patients management represents a promising result; however, further randomized prospective studies performed on larger series for a prolonged time and on individual pathology groups are mandatory to confirm these data.
References
Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol 2015;50(6):657-67. doi: 10.3109/00365521.2015.1019918
Varbanova M, Frauenschläger K, Malfertheiner P. Chronic gastritis - an update. Best Pract Res Clin Gastroenterol 2014;28(6):1031-42. DOI: 10.1016/j.bpg.2014.10.005
Rugge M, Savarino E, Sbaraglia M, Bricca L, Malfertheiner P. Gastritis: The clinico-pathological spectrum. Dig Liver Dis 2021;Oct;53(10):1237-46. doi: 10.1016/j.dld.2021.03.007
Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathology 2005;36(3):228–33. doi: 10.1016/j.humpath.2004.12.008
Lahner E, Carabotti M, Annibale B. Atrophic body gastritis: clinical presentation, diagnosis, and outcome. EMJ Gastroenterology 2017;6:1-8. doi:10.33590/ emjgastroenterol/10314623
Lahner E, Conti L, Annibale B, Corleto VD. Current Perspectives in Atrophic Gastritis. Curr Gastroenterol Rep 2020;22(8): 38. doi: 10.1007/s11894-020-00775-1
Lahner E, Zagari RM, Zullo A et al. Chronic Atrophic Gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI]. Dig Liver Dis 2019;51(12):1621-32. doi: 10.1016/j.dld.2019.09.016
Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis 2012;13(1):2-9. doi: 10.1111/j.1751-2980.2011.00550.x
Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015;20(1):25–40. doi: 10.15430/JCP.2015.20.1.25
Vannella L, Lahner E, Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World J Gastroenterol 2012;18(12):1279-1285. doi:10.3748/wjg.v18.i12.1279
Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers Prev 2006;15(6):1083–94. doi: 10.1158/1055-9965.EPI-05-0931
Weck MN, Stegmaier C, Rothenbacher D, Brenner H. Epidemiology of chronic atrophic gastritis: population based study among 9444 older adults from Germany. Aliment Pharmacol Ther 2007;26(6):879–87. doi: 10.1111/j.1365-2036.2007.03430.x
de Vries AC, Meijer GA, Looman CWN, et al. Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut 2007,56(12):1665–70. doi: 10.1136/gut.2007.127167
Marques-Silva L, Areia M, Elvas L, Dinis-Ribeiro M. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2014;26(4):378–87. doi: 10.1097/MEG.0000000000000065
Telaranta-Keerie A, Kara R, Paloheimo L, et al. Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol 2010;45(9):1036–41. doi: 10.3109/00365521.2010.487918
Notsu T, Adachi K, Mishiro T, et al. Prevalence of Autoimmune Gastritis in Individuals Undergoing Medical Checkups in Japan. Intern Med 2019;58(3):1817-23. doi: 10.2169/internalmedicine.2292-18
Wolf E-M, Plieschnegger W, Geppert M., et al. Changing prevalence patterns in endoscopic and histological diagnosis of gastritis? Data from a cross-sectional Central European multicentre study. Dig Liver Dis 2014;46(5):412–8. doi: 10.1016/j.dld.2013.12.017
Adamu MA, eck MN, Gao L, Brenner H. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol 2010;25(7):439–48. doi: 10.1007/s10654-010-9482-0
Miceli E, Lenti MV, Padula D, et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol 2012;10(7):812–4. doi: 10.1016/j.cgh.2012.02.018
Toh BH. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev 2014;13(4-5):459–62. doi: 10.1016/j.autrev.2014.01.048
Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis—pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013;10(9):529–41. doi: 10.1038/nrgastro.2013.101
Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochenschr 2016;166(13-14):424–30. doi: 10.1007/s10354-016-0515-5
Lenti MV, Rugge M, Lahner E, et al. Autoimmune gastritis. Nat Rev Dis Primers 2020;6(1):1–19. doi: 10.1038/s41572-020-0187-8
Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisegna JR. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol 2017;10:19–27. doi: 10.2147/CEG.S109123
Livzan MA, Gaus OV, Mozgovoi SI, Bordin DS. Chronic Autoimmune Gastritis: Modern Diagnostic Principles. Diagnostics (Basel) 2021;15(11):1-15. doi: 10.3390/diagnostics11112113
Massironi S, Zilli A, Elvevi A, Invernizzi P. The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmun Rev 2019;18(3):215–22. doi: 10.1016/j.autrev.2018.08.011
Oksanen AM, Haimila KE, Rautelin HIK, Partanen JA. Immunogenetic characteristics of patients with autoimmune gastritis. World J Gastroenterol 2010;16(3):354–8. doi: 10.3748/wjg.v16.i3.354
Toh BH, Sentry JW, Alderuccio F. The causative H+/K+ ATPase antigen in the pathogenesis of autoimmune gastritis. Immunol Today 2000;21(7):348–54. DOI: 10.1016/s0167-5699(00)01653-4
D’Elios MM, Bergman MP, Azzurri A, et al. H(+),K(+)-ATPase [proton pump] is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology 2001;120(2):377–86. DOI: 10.1053/gast.2001.21187
van Driel IR, Baxter AG, Laurie KL, et al. Immunopathogenesis, loss of T cell tolerance and genetics of autoimmune gastritis. Autoimmun Rev 2002;1(5):290–7. doi: 10.1016/s1568-9972(02)00066-6
Rusak E, Chobot A, Krzywicka A, Wenzlau J. Anti-parietal cell antibodies – diagnostic significance. Adv Med Sci 2016;61(2):175–9. doi: 10.1016/j.advms.2015.12.004
Lahner E, Norman GL, Severi C, Encabo S. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 2009;104(8):2071–9. DOI:10.1038/ajg.2009.231
Hershko C, Ronson A, Souroujon M, Maschler I, Heyd J, Patz J. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood 2006;107(4):1673–9. doi.org/10.1182/blood-2005-09-3534
Marignani M, Delle Fave G, Mecarocci S, et al. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. Am J Gastroenterol 1999;94(3):766–72.
Betesh AL, Santa Ana CA, Cole JA, Fordtran JS. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr 2015;102(1):9–19. DOI: 10.3945/ajcn.114.097394
Annibale B, Capurso G, Delle Fave G. The stomach and iron deficiency anaemia: a forgotten link. Dig Liver Dis 2003; 35(4):288-95. doi: 10.1016/s1590-8658(03)00067-7
Kulnigg-Dabsch S, Resch M, Oberhuber G, Klinglmueller F, Gasche A, Gasche C. Iron deficiency workup reveals high incidence of autoimmune gastritis with parietal cell antibody as reliable screening test. Semin Hematol 2018;55(4):256–61. doi: 10.1053/j.seminhematol.2018.07.003
Bizzaro N, Antico A. Diagnosis and classification of pernicious anemia. Autoimmun Rev 2014;13(4-5):565–8. doi: 10.1016/j.autrev.2014.01.042
Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 2007;85(1):193-200. DOI: 10.1093/ajcn/85.1.193
Stabler SP. Clinical Practice. Vitamin B12 Deficiency. N Engl J Med 2013;368(2):149–60. doi: 10.1056/NEJMcp1113996
Kaye PV, Garsed K, Ragunath K, Jawhari A, Pick B, Atherton JC. The clinical utility and diagnostic yield of routine gastric biopsies in the investigation of iron deficiency anemia: a case-control study. Am J Gastroenterol 2008;103(11):2883-89. doi: 10.1111/j.1572-0241.2008.02121.x
Niemelä S, Karttunen T, Kerola T. Helicobacter pylori-associated gastritis. Evolution of histologic changes over 10 years. Scand J Gastroenterol 1995;30(6):542–9. doi: 10.3109/00365529509089787
Amedei A, Bergman MP, Appelmelk BJ, et al. Molecular mimicry between Helicobacter pylori antigens and H+,K+-adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003;198(8):1147-56. doi: 10.1084/jem.20030530
Zhang Y, Weck MN, Schottker B, Rothenbacher D, Brenner H. Gastric parietal cell antiobodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev 2013;22(5):821-6. doi: 10.1158/1055-9965.EPI-12-1343
Furuta T, Baba S, Yamade M, et al. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther 2018;48(3):370–7. doi: 10.1111/apt.14849
Wang SM, Roth MJ, Murphy GA, et al. Serologic profile of antiparietal cell antibodies, pepsinogens, and H. pylori and risk of upper gastrointestinal cancer: a nested case–control study in China. Cancer Epidemiol Biomarkers Prev 2019;28(12):2022–9. doi.org/10.1158/1055-9965.EPI-19-0512
Rodriguez-Castro KI, Franceschi M, Noto A, et al. Clinical manifestations of chronic atrophic gastritis. Acta Biomed 2018;89(Suppl 8):88–92. doi: 10.23750/abm.v89i8-S.7921
Carabotti M, Esposito G, Lahner E, et al. Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study. Scand J Gastroenterol 2019;54(1):35–40. doi: 10.1080/00365521.2018.1553062
Kalkan Ç, Soykan I, Soydal Ç, Özkan E, Kalkan E. Assessment of Gastric Emptying in Patients with Autoimmune Gastritis. Dig Dis Sci 2016;61(6):1597–602. doi: 10.1007/s10620-015-4021-1
Pilotto V, Maddalo G, Orlando C, et al. Objective evidence of gastro-esophageal reflux disease is rare in patients with autoimmune gastritis. J Gastrointest Liver Dis 2021;30(1):30–6. DOI: 10.15403/jgld-3033
Cavalcoli F, Zilli A, Conte D, Massironi S. Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: a review. World J Gastroenterol 2017;23(4):563–72. doi: 10.3748/wjg.v23.i4.563
Rustgi SD, Bijlani P, Shah SC. Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management. Therap Adv Gastroenterol 2021;14:1-12. doi: 10.1177/17562848211038771
Barchi A, Miraglia C, Violi A, et al. A non-invasive method for the diagnosis of upper GI diseases. Acta Biomed 2018;89(8-S):40–43. doi: 10.23750/abm.v89i8-S.7917
Agréus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47(2):136–47. doi: 10.3109/00365521.2011.645501
Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kuriharaet M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004; 11(3):141-7. doi: 10.1258/0969141041732184
Syrjänen K. A Panel of Serum Biomarkers (Gastropanel®) in Non-invasive Diagnosis of Atrophic Gastritis. Systematic Review and Meta-analysis. Anticancer Res 2016;36(10):5133–44. doi: 10.21873/anticanres.11083
Storskrubb T, Aro P, Ronkainen J, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008;43(12):1448–55. doi: 10.1080/00365520802273025
Loong TH, Soon NC, Nik Mahmud NRKN, et al. Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus. Biomed Rep 2017;7(5):460-8. doi: 10.3892/br.2017.985
Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther 2017;46(7):657-67. doi: 10.1111/apt.14248
Koivurova OP, Koskela R, Blomster T, et al. Serological biomarker panel in diagnosis of atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients: clinical validation of the new-generation Gastropanel® test. Anticancer Res 2021;41(11):5527–37. doi: 10.21873/anticanres.15366
Antico A, Tozzoli R, Villalta D, Tonutti E, Tampoia M, Bizzaro N. Efficacia diagnostica di un profilo sierologico specifico per la diagnosi di gastrite cronica autoimmune. RIMeL/IJLaM 2010;6(3):198-204.
Ju Yup L, Nayoung K, Hye Seung L, et al. Correlations among endoscopic, histologic and serologic diagnoses for the assessment of atrophic gastritis. J Cancer Prev 2014;19(1):47-55. doi: 10.15430/jcp.2014.19.1.47
Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationship among serum pepsinogen I, serum pepsinogen II and serum gastric mucosa histology. Gastroenterology 1982;83 (1 Pt 2):204-9.
Sipponen P, Laxén F, Huotari K, Härkönen M. Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and Helicobacter pylori infection. Scand J Gastroenterol 2003;38(12):1209–16. doi: 10.1080/00365520310007224
Peracchi M, Gebbia C, Basilisco G, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005;152(3):443–8. doi: 10.1530/eje.1.01862
Zhang C, Huang Y, Long J, et al. Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression. Oncol Lett 2019;17(2):1497–504. doi: 10.3892/ol.2018.9795
Santarelli L, Gabrielli M, Cremonini F, et al. Atrophic gastritis as a cause of hyperhomocysteinaemia. Aliment Pharmacol Ther 2004;19(1):107–11. doi: 10.1046/j.1365-2036.2003.01820.x
Orgler E, Dabsch S, Malfertheiner P, Schulz C. Autoimmune Gastritis: Update and New Perspectives in Therapeutic Management. Curr Treat Options Gastroenterol 2023;21:64-77. DOI:10.1007/s11938-023-00406-4
Masuy I, Van Oudenhove L, Tack J. Review article: treatment options for functional dyspepsia. Aliment Pharmacol Ther 2019;49(9):1134–72. doi: 10.1111/apt.15191
Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematology Am Soc Hematol Educ Program 2016;2016(1):57–66. doi: 10.1182/asheducation-2016.1.57
Okam MM, Koch TA, Tran M-H. Iron Supplementation, Response in Iron-Deficiency Anemia: Analysis of Five Trials. Am J Med 2017;130(8):991.e1- 991.e8. doi: 10.1016/j.amjmed.2017.03.045
Bensky MJ, Ayalon-Dangur I, Ayalon-Dangur R, et al. Comparison of sublingual vs. intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency. Drug Deliv Transl Res 2019;9(3):625–30. doi: 10.1007/s13346-018-00613-y
Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Practice 2006;23(3):279-85. doi: 10.1093/fampra/cml008
Masuy I, Van Oudenhove L, Tack J. Review article: treatment options for functional dyspepsia. Aliment Pharmacol Ther 2019;49(9);1134–72. doi: 10.1111/apt.15191
Hellström PM, Hendolin P, Kaihovaara P, et al. Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study of Helicobacter-associated atrophic gastritis. Scand J Gastroenterol 2017;52(2):230–7. doi: 10.1080/00365521.2016.1249403
Linderborg K, Marvola T, Marvola M, Salaspuro M, Färkkilä M, Väkeväinenet S. Reducing carcinogenic acetaldehyde exposure in the achlorhydric stomach with cysteine. Alcohol Clin Exp Res 2011;35(3):516-22. doi: 10.1111/j.1530-0277.2010.01368.x
Li M, Sun Z, Zhang H, Liu Z. Recent advances on polaprezinc for medical use (Review). Exp Ther Med 2021;22(6):1445-52. doi: 10.3892/etm.2021.10880
Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y, Ichinose M. Polaprezinc (Zinc L-Carnosine) Is a Potent Inducer of Anti-oxidative Stress Enzyme, Heme Oxygenase (HO)-1 — a New Mechanism of Gastric Mucosal Protection. J Pharmacol Sci 2009;110(3):285–94. doi: 10.1254/jphs.09056fp
Ooi TC, Chan KM, Sharif R. Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc l-carnosine: A Potential Cancer Chemopreventive Agent? Nutr Cancer 2017;69(2):201–10. doi: 10.1080/01635581.2017.1265132
Price AB. The Sydney System: histological division. J Gastroenterol Hepatol 1991;6(3):209-22. doi: 10.1111/j.1440-1746.1991.tb01468.x
Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56(5):631-6. doi: 10.1136/gut.2006.106666
Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: A twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010;31(10):1104–11. doi: 10.1111/j.1365-2036.2010.04277.x
Rugge M, Sugano K, Scarpignato C, Sacchi D, Oblitas WJ, Naccarato AG. Gastric cancer prevention targeted on risk assessment: Gastritis OLGA staging. Helicobacter 2019;24(2):e12571. doi: 10.1111/hel.12571
Syrjänen K. Serum Biomarker Panel (GastroPanel®) and Slow-Release L-cysteine (Acetium® Capsule): Rationale for the Primary Prevention of Gastric Cancer. J Gastrointest Dig Syst 2017;6(Suppl):172–92. DOI: 10.4172/2161-069X-C1-059
Pilotto A, Maggi S, Noale M, Franceschi M, Parisi G, Crepaldi G. Development and validation of a new questionnaire for the evaluation of upper gastrointestinal symptoms in the elderly population: a multicenter study. J Gerontol A Biol Sci Med Sci 2010;65(2):174-8. doi: 10.1093/gerona/glp073
De Marchi D, Panozzo MP, Antico A, Tozzoli R. Valutazione di un nuovo metodo immunometrico per la misura dei marcatori biochimico/sierologici di gastrite atrofica. La Rivista Italiana della Medicina di Laboratorio 2019;15(4):284-93. DOI: 10.23736/S1825-859X.19.00036-7
Shen W, Zhao X, Han Z, et al. Efficacy and safety of polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial. Med Eng Phys 2022;110:1-5. doi: 10.1016/j.medengphy. 2022.103860
Salaspuro M. Acetaldehyde as a common denominator and cumulative carcinogen in digestive tract cancers. Scand J Gastroenterol 2009;44(8):912–25. DOI: 10.1080/00365520902912563
Di Mario F, Crafa P, Grillo S, et al. Recovery of gastric function in patients affected by chronic atrophic gastritis using l-cysteine (Acetium®): one year survey in comparison with a control group. Acta Biomed 2022:93(3):e2022184. doi: 10.23750/abm.v93i3.12812
Di Mario F, Rodriguez-Castro KI, Franceschi M, et al. Improvement of Symptoms in Patients Affected by Chronic Atrophic Gastritis Using L-Cysteine (Acetium®). Dig Dis 2023;41829:198–205. doi: 10.1159/000528168
Efthymakis K, Neri M. The role of Zinc L-Carnosine in the prevention and treatment of gastrointestinal mucosal disease in humans: a review. Clin Res Hepatol Gastroenterol 2022;46(7):2-10. doi: 10.1016/j.clinre.2022.101954
Shen W, Zhao X, Han Z, et al. Efficacy and safety of polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial. Med Engineering Physics 2022,110:1-5. doi: 10.1016/j.medengphy.2022.103860
Mahmoud A, Abuelazm M, Ahmed AAS, et al. Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2022;14(19):4126-44. doi: 10.3390/nu14194126
How to Cite
Issue
Section
License
Copyright (c) 2024 Maria Piera Panozzo, Stefano Rossi, Kryssia Isabel Rodriguez Castro, Marilisa Franceschi, Alessandra Violi, Antonio Ferronato, Lorenzo Brozzi, Lorella Franzoni, Francesco Di Mario, Pellegrino Crafa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
